uniQure N.V. (QURE)
NASDAQ:QURE
Want to see QURE full AI Analyst Report?
QURE Stock Chart & Stats
$17.58
-$1.39(-7.88%)
At close: 4:00 PM EST
$17.58
-$1.39(-7.88%)
Day’s Range― - ―
52-Week Range$8.73 - $71.50
Previous CloseN/A
Volume1.49M
Average Volume (3M)1.95M
Market Cap
$1.68B
Enterprise Value$1.71B
Total Cash (Recent Filing)$586.55M
Total Debt (Recent Filing)$63.32M
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Aug 04, 2026EPS Estimate
-0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.51
Shares Outstanding62,529,408
10 Day Avg. Volume1,642,203
30 Day Avg. Volume1,954,360
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)6.92
Price to Sales (P/S)85.48
P/FCF Ratio-7.73
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue94.36
Enterprise Value/Gross Profit127.27
Enterprise Value/Ebitda-11.02
Forecast
1Y Price Target
$39.88Price Target Upside126.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-3.51
Revenue Forecast (FY)$20.76M
Bulls Say, Bears Say
Bulls Say
AMT-130 Regulatory ProgressA successful pre-submission meeting and a planned Q3 2026 UK MAA filing for AMT-130 create a concrete regulatory pathway. Positive three‑year data that slowed progression materially de-risks one of uniQure's lead assets and strengthens the company's long‑term commercialization prospects and partner leverage.
Partnered Commercialization (Hemgenix)Outlicensing Hemgenix commercialization to CSL reduces uniQure's need to build a global sales force, lowering fixed costs and conserving cash. This durable asset-light model lets uniQure focus capital on R&D and clinical programs while still capturing product economics through partnership payments and royalties.
Manageable Leverage & Asset BaseRelatively modest debt and positive equity alongside a sizable asset base provide a structural balance-sheet cushion. Manageable leverage improves the company's ability to access financing or monetize assets to fund development programs without immediate solvency pressure, supporting near‑term program execution.
Bears Say
Sustained Cash BurnMaterial negative operating cash flow (TTM ~-$172M) indicates ongoing high cash burn to support trials. This persistent outflow forces reliance on external financing or asset disposals, raising dilution and execution risk and constraining the company’s ability to expand or sequence multiple late‑stage programs.
Large Operating LossesDeep and sustained operating losses mean the company is not yet on a path to profitability. Continued negative margins reduce internal funding for R&D and commercialization, increase dependence on partners and investors, and can force program reprioritization or slowdowns if external capital becomes constrained.
Modest Revenue BaseTTM revenue of roughly $18M is small relative to clinical and G&A spending, so product-derived cash flow cannot yet fund operations. Reliance on collaboration, milestone and partner economics creates revenue volatility and delays self‑funding until successful approvals scale sustained commercial sales.
uniQure News
QURE FAQ
What was uniQure N.V.’s price range in the past 12 months?
uniQure N.V. lowest stock price was $8.73 and its highest was $71.50 in the past 12 months.
What is uniQure N.V.’s market cap?
uniQure N.V.’s market cap is $1.68B.
When is uniQure N.V.’s upcoming earnings report date?
uniQure N.V.’s upcoming earnings report date is Aug 04, 2026 which is in 54 days.
How were uniQure N.V.’s earnings last quarter?
uniQure N.V. released its earnings results on May 05, 2026. The company reported -$0.85 earnings per share for the quarter, beating the consensus estimate of -$0.865 by $0.015.
Is uniQure N.V. overvalued?
According to Wall Street analysts uniQure N.V.’s price is currently Undervalued.
Does uniQure N.V. pay dividends?
uniQure N.V. does not currently pay dividends.
What is uniQure N.V.’s EPS estimate?
uniQure N.V.’s EPS estimate is -0.84.
How many shares outstanding does uniQure N.V. have?
uniQure N.V. has 62,529,408 shares outstanding.
What happened to uniQure N.V.’s price movement after its last earnings report?
uniQure N.V. reported an EPS of -$0.85 in its last earnings report, beating expectations of -$0.865. Following the earnings report the stock price went up 2.321%.
Which hedge fund is a major shareholder of uniQure N.V.?
Currently, no hedge funds are holding shares in QURE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
uniQure Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.88 (126.82% Upside)
$39.88 (126.82% Upside)
Blogger Sentiment
Bullish
QURE Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 89.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $279.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.8%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
56.56%
12-Months-Change
Fundamentals
Return on Equity
-145.81%
Trailing 12-Months
Asset Growth
28.63%
Trailing 12-Months
Company Description
uniQure N.V.
uniQure N.V. operates as a specialized gene therapy company, dedicated to pioneering therapeutic solutions for individuals grappling with severe genetic and other debilitating illnesses. The firm's most advanced project, Etranacogene dezaparvovec (designated as AMT-061), is currently progressing through a crucial Phase III pivotal trial, known as HOPE-B, targeting the treatment of hemophilia B. In addition to its flagship program, uniQure is actively developing several other candidates. This includes AMT-130, a gene therapy undergoing Phase I/II clinical assessment for Huntington's disease, and AMT-060, also in Phase I/II clinical trials for hemophilia B. The company's pipeline further extends to AMT-210 for Parkinson's disease, AMT-260 aimed at temporal lobe epilepsy, and AMT-161, which addresses amyotrophic lateral sclerosis. Furthermore, AMT-240 is an early-stage, preclinical product candidate focused on autosomal dominant Alzheimer's disease. Established in 1998, uniQure N.V. maintains its corporate headquarters in Amsterdam, Netherlands.
QURE Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call communicated major positive clinical advances (notably strong 3‑year AMT‑130 efficacy, supportive Fabry and TLE data) and a strengthened balance sheet, but these were tempered by significant regulatory resistance from the FDA (recommendation for a sham‑controlled Phase III), safety‑related pauses/holds in two programs (AMT‑191 dosing pause and AMT‑162 hold), and a substantial year‑over‑year revenue decline. Management emphasized active regulatory engagement, continued data generation (4‑year AMT‑130 analysis) and pursuit of ex‑U.S. pathways and early access options, while acknowledging material uncertainty around Phase III design, cost and feasibility.View all QURE earnings summariesQURE Stock 12 Month Forecast
Average Price Target
$39.88
▲(126.82% Upside)
Technical Analysis
Ownership Overview
2.46% Insiders
16.57% Mutual Funds
59.41% Other Institutional Investors
14.99% Public Companies and
Individual Investors